Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
APS
MCID: ANT006
MIFTS: 55

Antiphospholipid Syndrome (APS)

Categories: Blood diseases, Cardiovascular diseases, Genetic diseases, Immune diseases, Rare diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Antiphospholipid Syndrome

About this section

MalaCards integrated aliases for Antiphospholipid Syndrome:

Name: Antiphospholipid Syndrome 12 73 20 43 53 36 54 44 15 17 70
Antiphospholipid Antibody Syndrome 12 20 43 62
Hughes Syndrome 20 43 53
Familial Antiphospholipid Syndrome 20 70
Acromegaloid Facial Appearance Syndrome 70
Lupus Anticoagulant, Familial 20
Anti-Phospholipid Syndrome 43
Aps 20

Classifications:

MalaCards categories:
Global: Rare diseases Genetic diseases
Anatomical: Cardiovascular diseases Immune diseases Blood diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:2988
KEGG 36 H01697
MeSH 44 D016736
NCIt 50 C61283
SNOMED-CT 67 201450008
ICD10 32 D68.61
UMLS 70 C0085278 C0796280 C2930802
Sources

Summaries for Antiphospholipid Syndrome

About this section
MedlinePlus Genetics : 43 Antiphospholipid syndrome is a disorder characterized by an increased tendency to form abnormal blood clots (thromboses) that can block blood vessels. This clotting tendency is known as thrombophilia. In antiphospholipid syndrome, the thromboses can develop in nearly any blood vessel in the body, but most frequently occur in the vessels of the lower limbs. If a blood clot forms in the vessels in the brain, blood flow is impaired and can lead to stroke. Antiphospholipid syndrome is an autoimmune disorder. Autoimmune disorders occur when the immune system attacks the body's own tissues and organs.Women with antiphospholipid syndrome are at increased risk of complications during pregnancy. These complications include pregnancy-induced high blood pressure (preeclampsia), an underdeveloped placenta (placental insufficiency), early delivery, or pregnancy loss (miscarriage). In addition, women with antiphospholipid syndrome are at greater risk of having a thrombosis during pregnancy than at other times during their lives. At birth, infants of mothers with antiphospholipid syndrome may be small and underweight.A thrombosis or pregnancy complication is typically the first sign of antiphospholipid syndrome. This condition usually appears in early to mid-adulthood but can begin at any age.Other signs and symptoms of antiphospholipid syndrome that affect blood cells and vessels include a reduced amount of cells involved in blood clotting called platelets (thrombocytopenia), a shortage of red blood cells (anemia) due to their premature breakdown (hemolysis), and a purplish skin discoloration (livedo reticularis) caused by abnormalities in the tiny blood vessels of the skin. In addition, affected individuals may have open sores (ulcers) on the skin, migraine headaches, heart disease, or intellectual disability. Many people with antiphospholipid syndrome also have other autoimmune disorders such as systemic lupus erythematosus.Rarely, people with antiphospholipid syndrome develop thromboses in multiple blood vessels throughout their body. These thromboses block blood flow in affected organs, which impairs their function and ultimately causes organ failure. These individuals are said to have catastrophic antiphospholipid syndrome (CAPS). CAPS typically affects the kidneys, lungs, brain, heart, and liver, and is fatal in over half of affected individuals. Less than 1 percent of individuals with antiphospholipid syndrome develop CAPS.

MalaCards based summary : Antiphospholipid Syndrome, also known as antiphospholipid antibody syndrome, is related to catastrophic antiphospholipid syndrome and thrombotic microangiopathy, and has symptoms including unspecified visual loss An important gene associated with Antiphospholipid Syndrome is APOH (Apolipoprotein H), and among its related pathways/superpathways are Response to elevated platelet cytosolic Ca2+ and Collagen chain trimerization. The drugs Acetaminophen and Warfarin have been mentioned in the context of this disorder. Affiliated tissues include endothelial, heart and placenta, and related phenotypes are Decreased viability and Decreased viability

Disease Ontology : 12 An autoimmune disease that is characterized by recurrent venous or arterial thrombosis and/or fetal losses associated with characteristic elevated levels of antibodies directed against membrane anionic phospholipids (anticardiolipin).

GARD : 20 Antiphospholipid syndrome (APS) is an autoimmune disorder. Signs and symptoms vary, but may include blood clots, miscarriage, rash, chronic headaches, dementia, and seizures. APS occurs when your body's immune system makes antibodies that attack phospholipids. Phospholipids are a type of fat found in all living cells, including blood cells and the lining of blood vessels. Most cases of APS occur in people with no family history of the disorder, however there are rare cases of APS clustering in a family. A widely accepted explanation for APS is that it is caused by a combination of gene mutations (making one more susceptible to APS) and an environmental exposure (such as to a virus ). Currently there is not a cure for APS. The goal of treatment is to prevent blood clots from forming and to keep existing clots from getting larger.

NINDS : 53 Antiphospholipid syndrome (APS) is an autoimmune disorder caused when antibodies -- immune system cells that fight off bacteria and viruses -- mistakenly attack healthy body tissues and organs.  In APS, specific antibodies activate the inner lining of blood vessels, which leads to the formation of blood clots in arteries or veins.  APS is sometimes called “sticky blood syndrome,” because of the increased tendency to form blood clots in the veins and arteries.  The symptoms of APS are due to the abnormal blood clotting.  Clots can develop in the veins of the legs and lungs, or in the placenta of pregnant women.  One of the most serious complications of APS occurs when a clot forms in the brain and causes a stroke.  Other neurological symptoms include chronic headaches, dementia (similar to the dementia of Alzheimer’s disease), and seizures.  Infrequently, individuals will develop chorea (a movement disorder in which the body and limbs writhe uncontrollably), cognitive dysfunction (such as poor memory), transverse myelitis, depression or psychosis, optic neuropathy, or sudden hearing loss.  In pregnant women, clots in the placenta can cause miscarriages.  APS is diagnosed by the presence of a positive antiphospholipid antibody and either a history of blood clots in an artery or vein or a history of multiple miscarriages or other pregnancy problems.  Some individuals will have a characteristic lacy, net-like red rash called livedo reticularis over their wrists and knees.

KEGG : 36 Antiphospholipid syndrome (APS) is characterized by a variety of clinical and immunological manifestations. The clinical hallmarks of this syndrome are thrombosisand poor obstetric outcomes in the presence of antiphospholipid antibodies. APS can occur within the context of several diseases, mainly autoimmune disorders, and is then called secondary APS. About 40% of patients with systemic lupus erythematosus (SLE) have antiphospholipid antibodies, but less than 40% of them will eventually have thrombotic events. On the other hand, it may be also be present without any recognizable disease, or so-called primary APS. Pregnancy complications in APS, such as recurrent unexplained abortions, fetal loss, preeclampsia, and premature birth, have been attributed to placental thrombosis and infarcts, and management of these patients is based on attenuating the procoagulant state. Treatment with low-dose aspirin (LDA) and heparinoids has become a conventional option for pregnant women with APS. Possible future therapies for non-pregnant patients with antiphospholipid syndrome are statins, rituximab, and new anticoagulant drugs.

PubMed Health : 62 About antiphospholipid antibody syndrome: Antiphospholipid (AN-te-fos-fo-LIP-id) antibody syndrome (APS) is an autoimmune disorder. Autoimmune disorders occur if the body's immune system makes antibodies that attack and damage tissues or cells. Antibodies are a type of protein. They usually help defend the body against infections. In APS, however, the body makes antibodies that mistakenly attack phospholipids—a type of fat. Phospholipids are found in all living cells and cell membranes, including blood cells and the lining of blood vessels. When antibodies attack phospholipids, cells are damaged. This damage causes blood clots to form in the body's arteries and veins. (These are the vessels that carry blood to your heart and body.) Usually, blood clotting is a normal bodily process. Blood clots help seal small cuts or breaks on blood vessel walls. This prevents you from losing too much blood. In APS, however, too much blood clotting can block blood flow and damage the body's organs.

Wikipedia : 73 Antiphospholipid syndrome, or antiphospholipid antibody syndrome (APS or APLS), is an autoimmune,... more...

Sources

Related Diseases for Antiphospholipid Syndrome

About this section

Diseases in the Antiphospholipid Syndrome family:

Antiphospholipid Syndrome, Familial

Diseases related to Antiphospholipid Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 989)
# Related Disease Score Top Affiliating Genes
1 catastrophic antiphospholipid syndrome 32.4 MTHFR F5 F3 CFH CD40LG APOH
2 thrombotic microangiopathy 31.4 VWF THBD F3 ADAMTS13
3 syphilis 31.4 F2 CD40LG APOH
4 eclampsia 31.3 THBD SERPINC1 MTHFR F2
5 heart valve disease 31.2 VWF F2 APOH
6 amaurosis fugax 31.1 MTHFR F5
7 placenta disease 31.1 SERPINC1 MTHFR F5 F3 F2 APOH
8 heparin-induced thrombocytopenia 31.0 SERPINC1 F3 F10 CD40LG
9 acute kidney failure 30.9 F2 CFH ADAMTS13
10 placental insufficiency 30.9 VWF SERPINC1 SELP F3 F2
11 pregnancy loss, recurrent 1 30.8 F5 APOH
12 respiratory failure 30.8 THBD F3 F2 ANXA5
13 endocarditis 30.8 VCAM1 SERPINC1 PLAT F2 APOH
14 osteonecrosis 30.8 SERPINC1 MTHFR F2
15 sudden sensorineural hearing loss 30.8 MTHFR F5 F2
16 splenic infarction 30.8 SERPINC1 F3 F2 APOH
17 budd-chiari syndrome 30.8 SERPINC1 MTHFR F5 F3 F2 APOH
18 sneddon syndrome 30.7 SERPINC1 F5 F2 APOH
19 hepatic infarction 30.7 SERPINC1 F3 F2 APOH
20 hemopericardium 30.7 F3 F2
21 pulmonary hypertension 30.7 VWF THBD SERPINC1 SELP PLAT F3
22 collagen disease 30.7 VWF THBD APOH
23 adult respiratory distress syndrome 30.6 THBD SELE F5 F2
24 toxic shock syndrome 30.6 SERPINC1 F3 CD40LG
25 branch retinal artery occlusion 30.6 SERPINC1 MTHFR F3 F2 APOH
26 nonbacterial thrombotic endocarditis 30.6 SERPINC1 F3 F2 APOH ADAMTS13
27 retinal artery occlusion 30.6 SERPINC1 MTHFR F5 F2 APOH
28 aortic valve insufficiency 30.6 VWF PON1 F3 F2
29 livedoid vasculitis 30.6 SERPINC1 MTHFR F2 APOH
30 portal hypertension 30.6 VWF F3 F2 ADAMTS13
31 ischemia 30.6 SELP SELE PON1 PLAT
32 hemolytic anemia 30.6 VWF THBD F3 F2 CFH CD40LG
33 placental abruption 30.6 THBD SERPINC1 MTHFR F5 F2 APOH
34 coronary thrombosis 30.6 VWF SERPINC1 SELP PLAT F3
35 retinal vein occlusion 30.6 SERPINC1 MTHFR F5 F3 F2 APOH
36 purpura 30.6 VWF THBD SERPINC1 PROCR F3 F2
37 mixed connective tissue disease 30.5 CD40LG APOH ADAMTS13
38 acquired hemophilia 30.5 F5 F3 F10
39 may-thurner syndrome 30.5 F5 APOH
40 hemophilia a 30.5 VWF F5 F3
41 ischemic colitis 30.5 SERPINC1 F5 F2 APOH
42 mitral valve stenosis 30.5 VWF SERPINC1 SELP F3 F2
43 anuria 30.5 F3 F2 ADAMTS13
44 pulmonary embolism 30.5 VWF THBD SERPINC1 PLAT MTHFR F5
45 end stage renal disease 30.5 THBD PON1 MTHFR CFH
46 acquired hemophilia a 30.5 F5 F3
47 kidney cortex necrosis 30.4 F2 ADAMTS13
48 limb ischemia 30.4 VWF SELE PLAT F2
49 central retinal artery occlusion 30.4 SERPINC1 PLAT MTHFR F2
50 thrombophlebitis 30.4 VWF SERPINC1 PLAT MTHFR F5 F3

Graphical network of the top 20 diseases related to Antiphospholipid Syndrome:



Diseases related to Antiphospholipid Syndrome
Sources

Symptoms & Phenotypes for Antiphospholipid Syndrome

About this section

UMLS symptoms related to Antiphospholipid Syndrome:


unspecified visual loss

GenomeRNAi Phenotypes related to Antiphospholipid Syndrome according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00240-S-1 9.28 CD40LG PON1
2 Decreased viability GR00249-S 9.28 F10 F5
3 Decreased viability GR00381-A-1 9.28 PLAT PROCR
4 Decreased viability GR00381-A-3 9.28 PROCR
5 Decreased viability GR00386-A-1 9.28 MTHFR SELP

MGI Mouse Phenotypes related to Antiphospholipid Syndrome:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.36 ANXA2 CD40LG CFH F10 F2 F3
2 homeostasis/metabolism MP:0005376 10.3 ADAMTS13 ANXA2 APOH CD40LG CFH F10
3 growth/size/body region MP:0005378 10.22 ANXA2 CFH F2 F3 F5 MTHFR
4 hematopoietic system MP:0005397 10.21 ADAMTS13 ANXA2 ANXA5 CD40LG CFH F3
5 cellular MP:0005384 10.17 CD40LG F2 F3 PLAT PON1 SELE
6 immune system MP:0005387 10.1 ADAMTS13 ANXA5 CD40LG CFH F2 F3
7 mortality/aging MP:0010768 9.89 ADAMTS13 APOH CD40LG CFH F10 F2
8 integument MP:0010771 9.81 CD40LG F2 F3 F5 MTHFR PLAT
9 nervous system MP:0003631 9.36 CD40LG CFH F2 F3 F5 MTHFR
Sources

Drugs & Therapeutics for Antiphospholipid Syndrome

About this section

PubMed Health treatment related to Antiphospholipid Syndrome: 62

Antiphospholipid antibody syndrome (APS) has no cure. However, medicines can help prevent complications. The goals of treatment are to prevent blood clots from forming and keep existing clots from getting larger. You may have APS and another autoimmune disorder , such as lupus . If so, it's important to control that condition as well. When the other condition is controlled, APS may cause fewer problems. Research is ongoing for new ways to treat APS.

Drugs for Antiphospholipid Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 83)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Acetaminophen Approved Phase 4 103-90-2 1983
2
Warfarin Approved Phase 4 81-81-2 6691 54678486
3
Enoxaparin Approved Phase 4 9005-49-6 772
4
Apixaban Approved Phase 4 503612-47-3 10182969
5 Vaccines Phase 4
6 Pharmaceutical Solutions Phase 4
7 Soy Bean Phase 4
8 Fat Emulsions, Intravenous Phase 4
9 Soybean oil, phospholipid emulsion Phase 4
10 Parenteral Nutrition Solutions Phase 4
11
Acenocoumarol Approved, Investigational Phase 3 152-72-7 9052 54676537
12
tannic acid Approved Phase 2, Phase 3 1401-55-4
13
Benzocaine Approved, Investigational Phase 2, Phase 3 1994-09-7, 94-09-7 2337
14
Rivaroxaban Approved Phase 3 366789-02-8
15
Hydroxychloroquine Approved Phase 3 118-42-3 3652
16 Antivitamins K Phase 3
17 Antirheumatic Agents Phase 3
18 Immunoglobulins Phase 3
19 Antibodies, Antiphospholipid Phase 3
20 Antibodies Phase 3
21 Serine Proteinase Inhibitors Phase 3
22 Antithrombins Phase 3
23 Antithrombin III Phase 3
24 Factor Xa Inhibitors Phase 3
25 HIV Protease Inhibitors Phase 3
26
protease inhibitors Phase 3
27 Antiparasitic Agents Phase 3
28 Antimalarials Phase 3
29 Anti-Infective Agents Phase 3
30 Antiprotozoal Agents Phase 3
31 Autoantibodies Phase 3
32
Serine Investigational, Nutraceutical Phase 3 56-45-1 5951
33
rituximab Approved Phase 2 174722-31-7 10201696
34
Aspirin Approved, Vet_approved Phase 2 50-78-2 2244
35
Heparin Approved, Investigational Phase 2 9005-49-6 772 9812414
36
Certolizumab pegol Approved Phase 2 428863-50-7
37 Antineoplastic Agents, Immunological Phase 2
38 Hormones Phase 2
39 Calcium, Dietary Phase 2
40 Immunosuppressive Agents Phase 2
41 Immunologic Factors Phase 2
42 calcium heparin Phase 2
43
Calcium Nutraceutical Phase 2 7440-70-2 271
44
Sodium citrate Approved, Investigational 68-04-2
45
Lenograstim Approved, Investigational 135968-09-1
46
Vitamin K1 Approved, Investigational 84-80-0 5284607
47
Celecoxib Approved, Investigational 169590-42-5 2662
48
Rofecoxib Approved, Investigational, Withdrawn 162011-90-7 5090
49
Edoxaban Approved 480449-70-5
50
Clopidogrel Approved 120202-66-6, 113665-84-2 60606

Interventional clinical trials:

(show top 50) (show all 68)
# Name Status NCT ID Phase Drugs
1 Safety and Efficacy of Anti-Pandemic H1N1 Vaccination in Rheumatic Diseases Unknown status NCT01151644 Phase 4
2 Rivaroxaban in Antiphospholipid Syndrome Pilot Study: A Multicenter Feasibility Study of Rivaroxaban for Patients With Antiphospholipid Syndrome and Prior Arterial or Venous Thrombosis Completed NCT02116036 Phase 4 Rivaroxaban
3 Timing of Initiation of Low Molecular Weight Heparin Administration in Pregnant Women With Antiphospholipid Syndrome Completed NCT02326051 Phase 4 Enoxaparin;Enoxaparin
4 Dose-dependent Drug-drug Interaction Between Paracetamol and Warfarin in Adults Receiving Long-term Oral Anticoagulants: A Randomized Controlled Trial Completed NCT01104337 Phase 4 paracetamol;paracetamol;Placebo
5 Dose Intralipid Infusion Reduces Pregnancy Complications Caused by Antiphospholipid Antibody Syndrome? Recruiting NCT04274803 Phase 4 Intralipid, 20% Intravenous Emulsion;Conventional therapy of antiphospholipis syndrome
6 Use of Warfarin After the First Trimester in Pregnant Women With Antiphospholipid Syndrome Recruiting NCT02303171 Phase 4 Enoxaparin;Warfarin
7 Apixaban for the Secondary Prevention of Thromboembolism: a Prospective Randomized Outcome Pilot Study Among Patients With the AntiphosPholipid Syndrome Active, not recruiting NCT02295475 Phase 4 Apixaban;Warfarin
8 A Multicenter, Double-blind, Randomized and Parallel Controlled Study of Hydroxychloroquine Sulfate in the Treatment of Recurrent Miscarriage With Antiphospholipid Syndrome Not yet recruiting NCT04624269 Phase 4 Hydroxychloroquine Sulfate Tablets
9 Rivaroxaban Versus Acenocumarol for Secondary Thromboprophylaxis in Patients With Antiphospholipid Syndrome: a Randomized, Prospective, Phase III Study. Analysis of Stratification Prognostic Factors Completed NCT02926170 Phase 3 Rivaroxaban;acenocumarol
10 Hydroxychloroquine Versus Placebo: Impact on Thrombotic Relapse in Primary Antiphospholipid Syndrome Not yet recruiting NCT03540810 Phase 3 Hydroxychloroquine;Placebo
11 Rivaroxaban Versus Warfarin for Stroke Patients With Antiphospholipid Syndrome, With or Without SLE (RISAPS): a Randomised, Controlled, Open Label, Phase II/III, Non-inferiority Trial Not yet recruiting NCT03684564 Phase 2, Phase 3 Rivaroxaban;Warfarin
12 A Prospective Randomized Controlled Trial of Hydroxychloroquine in the Primary Thrombosis Prophylaxis of aPL Positive But Thrombosis-free Patients. Terminated NCT01784523 Phase 3 Hydroxychloroquine
13 A Prospective, Randomized Clinical Trial Comparing Rivaroxaban vs Warfarin in High Risk Patients With Antiphospholipid Syndrome Terminated NCT02157272 Phase 3 Experimental: Rivaroxaban
14 Efficiency of Hydroxychloroquine on the Endothelial Dysfunction in Antiphospholipid Syndrome (APLAQUINE) Unknown status NCT02595346 Phase 2 Hydroxychloroquine;placebo
15 Randomised Controlled Trial of Low Dose Steroid +Aspirin +Heparin Versus Aspirin+Heparin Amongst Pregnant Women With APS Unknown status NCT00180778 Phase 1, Phase 2 Low dose steroids
16 A Pilot Study of Rituximab for the Anticoagulation Resistant Manifestations of Antiphospholipid Syndrome (RITAPS) Completed NCT00537290 Phase 2 Rituximab
17 Eculizumab to Enable Renal Transplantation in Patients With History of Antiphospholipid Antibody Syndrome or Catastrophic Antiphospholipid Antibody Syndrome Completed NCT01029587 Phase 2 Eculizumab
18 Effects of Fluvastatin on Proinflammatory and Prothrombotic Markers in Antiphospholipid Syndrome Patients Completed NCT00674297 Phase 2 Fluvastatin
19 Low-molecular-weight Heparin Versus Unfractionated Heparin in Pregnant Women With History of Recurrent Abortion Secondary to Antiphospholipid Syndrome. A Randomized Controlled Trial Completed NCT01051778 Phase 2 enoxaparin 40mg plus low dose aspirin;Heparin calcium5,000 U twice daily plus low dose aspirin
20 Certolizumab to Prevent Pregnancy Complications in High-Risk Patients With APS or SLE - (IMPACT Study: IMProve Pregnancy in APS With Certolizumab Therapy) Recruiting NCT03152058 Phase 2 Certolizumab Pegol
21 Evaluation of the Benefit of Adjuvant Treatment With Hydroxychloroquine to the Usual Medical Management for Obtaining an Uncomplicated Term Pregnancy in Primary Obstetric Antiphospholipid Syndrome Not yet recruiting NCT04275778 Phase 2 Plaquenil 200Mg Tablet;Placebo oral tablet
22 An Open-Label Proof of Concept Phase IIa Trial of ALXN1007 for the Treatment of Non-criteria Manifestations of Antiphospholipid Syndrome Terminated NCT02128269 Phase 2
23 High Dose Cyclophosphamide & CAMPATH-1H With Hematopoietic Stem Cell Transplantation in Patients With Refractory Antiphospholipid Syndrome (APS): A Phase I Trial Withdrawn NCT00278616 Phase 1
24 The Influence of Antiphospholipid Antibodies on the Relationship Between Hyperurecemia, Gout and Metabolic Syndrome Unknown status NCT01818505
25 Assessement of a Multi-organ Screening Procedure for the Detection of Pre-clinical Ischaemia in Antiphospholipid Syndrome The COBRA Study (CardiO-Brain Renal Involvement in Antiphospholipid Syndrome) Unknown status NCT03348306
26 Prevalence of Lysosomal Hydrolase Alpha-glagtosidase Deficiency in Patients Unknown status NCT03384485
27 Detection Of Anti-Double Stranded Deoxyribonucleic Acid Antibodies In Autoimmune Rheumatic Diseases: Comparison Between Immunofluorescence And Enzyme Immunoassay Unknown status NCT03303508
28 Domain 1 of β2-Glycoprotein 1 Autoantibodies and Thrombin Generation Capacity in Patients With Antiphospholipid Antibodies Unknown status NCT03890601
29 A Randomized Clinical Trial of Using Preconceptional Enoxaparin AND Low Dose Aspirin 81mg in Patient With Antiphospholipid Syndrome(APS) Unknown status NCT01661439 low molecular weight heparin (enoxeparine)
30 Efficacy of EPA and DHA Supplementation in Systemic Lupus Erythematosus and Primary Antiphospholipid Syndrome Unknown status NCT01956188
31 Antiphospholipid Antibodies and Early Fetal Growth Restriction (<34 Weeks of Gestation). A Case Control Study. Unknown status NCT01538134
32 Antiphospholipid Antibodies and Early Severe Preeclampsia (< 34 Weeks of Gestation). A Case-Control Study. Unknown status NCT01538121
33 Prospective Observational Study About Pregnancy and Medically Assisted Conception in Rare Diseases Unknown status NCT02450396
34 Pilot Study of Cyclophosphamide in Patients With Life-Threatening Systemic Lupus Erythematosus or Antiphospholipid Antibody Syndrome Completed NCT00010400 Cyclophosphamide;filgrastim
35 Effect of Hydroxychloroquine on Thrombosis Prevention and Antiphospholipid Antibody Levels in Patients With Primary Antiphospholipid Syndrome: An Pilot Randomized Prospective Study. Completed NCT04153201 Hydroxychloroquine
36 Hypercoagulable Phenotype by Thrombinography (in Presence of C Protein Dynamic Inhibitory System): Marker of Venous Thrombosis Risk in Systemic Lupus and Antiphospholipid Syndrome? Case-control Study Completed NCT02892565
37 Obstetric Antiphospholipid Antibody Syndrome : Contribution of the Evaluation of ADAMTS13 Made at the Diagnosis of Pregnancy on Evaluation the Risk of Pre-eclampsia Completed NCT04319341
38 CI(R)CA : Coumadin Interaction With Rofecoxib, Celecoxib and Acetaminophen. A Prospective Double-blind, Placebo Controlled Study. Completed NCT01762891 Celecoxib;Acetaminophen;Rofecoxib;placebo
39 Accuracy of CoaguChek XS in Patients With Antiphospholipid Antibody Syndrome Completed NCT02139072
40 INR Determined by Plasma-based Methods Versus Newer Point-of-care Instruments in Patients With Antiphospholipid-antibody Syndrome Treated With Anticoagulants Completed NCT00878137
41 The Prognostic Value of PGF and sFlt1 Variations Induced by the First Low-molecular-weight-heparin Injections in Women With Obstetrical Antiphospholipids Antibody Syndrome Starting a New Pregnancy and Following Treatment in Accordance With International Recommendations Completed NCT02855047
42 Assessment of the Prevalence of Major Psychiatric Disorders in a Cohort of Women With Clinical Criteria Corresponding to Pure, Abortive-form, Obstetrical, Antiphospholipid Syndrome Completed NCT02833194
43 Medium-term Follow-up of Patients With Obstetric Antiphospholipid Syndrome: MRI Study of White Matter Completed NCT03600636
44 Monitoring Anticoagulant Therapy With Vitamin-K Antagonists in Patients With Antiphospholipid Syndrome Completed NCT01660061
45 Ocular Findings in Women With Primary Antiphospholipid Syndrome and Their Association to Bad Obstetric Outcome Completed NCT03459508
46 Evaluation of the Incidence of Cancer in the Follow-up of Women With 3 Consecutive Embryonic Demises Before 10 Weeks or 1 Fetal Death, According to Their Thrombophilia Status, With a Special Focus on Women With an Obstetric Antiphospholipid Symdrome (oAPS) Completed NCT03969498
47 Longitudinal Study of the Clinical and Haematological Cause of Women With Antiphospholipid Antibodies in Women Presenting as Recurrent Miscarriages. Completed NCT00180817
48 Antiphospholipid Syndrome Collaborative Registry (APSCORE) Completed NCT00076713
49 Retrospective Study of the Prevalence of Antiphospholipid Antibodies in the Population of Hemodialysis Patients at the CHU Brugmann Hospital Completed NCT03893357
50 Effect of Hydroxychloroquine on the Annexin A5 Resistance Assay in Antiphospholipid Antibody-Positive Patients With and Without Systemic Lupus Erythematosus Completed NCT01475149

Search NIH Clinical Center for Antiphospholipid Syndrome

Cochrane evidence based reviews: antiphospholipid syndrome

Sources

Genetic Tests for Antiphospholipid Syndrome

About this section
Sources

Anatomical Context for Antiphospholipid Syndrome

About this section

MalaCards organs/tissues related to Antiphospholipid Syndrome:

40
Endothelial, Heart, Placenta, Kidney, Skin, Bone, Bone Marrow
Sources

Publications for Antiphospholipid Syndrome

About this section

Articles related to Antiphospholipid Syndrome:

(show top 50) (show all 9015)
# Title Authors PMID Year
1
Effects of polyclonal IgG derived from patients with different clinical types of the antiphospholipid syndrome on monocyte signaling pathways. 61 54
20483743 2010
2
Antiphospholipid syndrome treatment beyond anticoagulation: are we there yet? 54 61
20353991 2010
3
Mode of interaction between beta2GPI and lipoprotein receptors suggests mutually exclusive binding of beta2GPI to the receptors and anionic phospholipids. 54 61
20223219 2010
4
Thyroid-associated autoimmune coagulation disorders. 61 54
19277469 2010
5
{beta}2 Glycoprotein I ({beta}2GPI) binds platelet factor 4 (PF4): implications for the pathogenesis of antiphospholipid syndrome. 61 54
19805618 2010
6
Etanercept and venous thromboembolism: a case series. 54 61
20157435 2010
7
Structural insights into recognition of beta2-glycoprotein I by the lipoprotein receptors. 61 54
19676115 2009
8
Autoantibodies against phosphatidylserine, prothrombin and phosphatidylserine-prothrombin complex: identical or distinct diagnostic tools for antiphospholipid syndrome? 61 54
19751711 2009
9
Pravastatin prevents miscarriages in antiphospholipid antibody-treated mice. 54 61
19556010 2009
10
Venous thromboembolism in young female while on oral contraceptives: high frequency of inherited thrombophilia and analysis of thrombotic events in 400 czech women. 61 54
19117968 2009
11
Vascular abnormalities, paraoxonase activity, and dysfunctional HDL in primary antiphospholipid syndrome. 54 61
19755700 2009
12
Beta2-glycoprotein I and annexin A5 phospholipid interactions: artificial and cell membranes. 61 54
19232551 2009
13
Prevalence of anticardiolipin antibodies in patient cohorts with distinct clinical manifestations of the antiphospholipid syndrome. 54 61
19758143 2009
14
[Cerebral venous thrombosis: when etiology makes the difference]. 54 61
19921552 2009
15
Microparticles in deep venous thrombosis, antiphospholipid syndrome and Factor V Leiden. 61 54
19811220 2009
16
The effects of phosphatidylserine-dependent antiprothrombin antibody on thrombin generation. 61 54
19644870 2009
17
Factor V Leiden mutation and antiphospholipid syndrome: risk factors for atherosclerotic and arterial thromboembolic disease. 61 54
19574060 2009
18
[Hypercoagulable workup in ophthalmology. When and what]. 61 54
19658050 2009
19
Thrombophilia testing in patients with venous thromboembolism. Findings from the RIETE registry. 54 61
19101711 2009
20
Thrombophilia: 2009 update. 54 61
19289024 2009
21
Novel autoantibodies against the activated coagulation factor IX (FIXa) in the antiphospholipid syndrome that interpose the FIXa regulation by antithrombin. 54 61
19155517 2009
22
Is there an overlap between sudden neurosensorial hearing loss and cardiovascular risk factors? 61 54
19005247 2009
23
[Pre-eclampsia screening in first and second trimester]. 61 54
18979429 2008
24
Resistance to annexin A5 anticoagulant activity: a thrombogenic mechanism for the antiphospholipid syndrome. 54 61
18827057 2008
25
Annexin A2: biology and relevance to the antiphospholipid syndrome. 61 54
18827060 2008
26
The antiphospholipid syndrome. 54 61
19028366 2008
27
Tissue factor in the antiphospholipid syndrome. 54 61
18827061 2008
28
Clinical challenge: heparin-induced thrombocytopenia type II (HIT II) or pseudo-HIT in a patient with antiphospholipid syndrome. 61 54
17828468 2008
29
Antibodies to anionic phospholipids and cofactors in kala-azar. Comparative study with malaria, toxoplasmosis and "autoimmune diseases". 61 54
19032825 2008
30
[Sagittal sinus thrombosis as a rare cause of postpartum headache: a case report]. 61 54
18853684 2008
31
The activated seven lupus anticoagulant assay detects clinically significant antibodies. 54 61
17895508 2008
32
Placental fas/fas ligand expression in early pregnancy losses. 61 54
18422813 2008
33
Venous thromboembolism during pregnancy. 61 54
18619081 2008
34
Etiological profile of stroke and its relation with prothrombotic states. 61 54
18759085 2008
35
The VWF/ADAMTS13 axis in the antiphospholipid syndrome: ADAMTS13 antibodies and ADAMTS13 dysfunction. 61 54
18341632 2008
36
Jejunal ischaemia-- rare aetiologies and a surgical dilemma. 61 54
18720940 2008
37
Recurrent ischemic colitis in a patient with leiden factor V mutation and systemic lupus erythematous with antiphospholipid syndrome. 61 54
18504175 2008
38
[Diagnosis of secondary antiphospholipid syndrome in children by means of screening tests]. 61 54
18354917 2008
39
Eighteen years of liver transplantation experience in patients with advanced Budd-Chiari syndrome. 54 61
18236386 2008
40
Modulation of fibrinolysis by the combined action of phospholipids and immunoglobulins. 54 61
18180621 2008
41
Multifactorial thrombophilia in a pregnancy: a case report. 54 61
17895510 2008
42
Traditional and nontraditional risk factors for atherosclerosis in patients with systemic lupus erythematosus. 61 54
19366077 2008
43
Sole existence of antithrombin antibody in patients with systemic lupus erythematosus showing tendency of its antigenic determinants directing against exosite II (antithrombin/heparin binding site) of thrombin. 54 61
18180618 2008
44
Thrombophilia and cerebral vein thrombosis. 61 54
18004053 2008
45
Acquired angioedema associated with primary antiphospholipid syndrome in a patient with antithrombin III deficiency. 54 61
18204284 2008
46
[Treatment of antiphospholipid syndrome]. 54 61
18303659 2007
47
Tissue factor: a link between C5a and neutrophil activation in antiphospholipid antibody induced fetal injury. 61 54
17536017 2007
48
Specificity and sensitivity of anti-beta2-glycoprotein I as compared with anticardiolipin antibody and lupus anticoagulant in Thai systemic lupus erythematosus patients with clinical features of antiphospholipid syndrome. 54 61
17332980 2007
49
Arterial thrombosis and the role of thrombophilia. 54 61
17768691 2007
50
Polymorphisms of the tissue factor pathway inhibitor gene are associated with venous thromboembolism in the antiphospholipid syndrome and carriers of factor V Leiden. 61 54
17762532 2007
Sources

Variations for Antiphospholipid Syndrome

About this section

Copy number variations for Antiphospholipid Syndrome from CNVD:

7
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 160790 22 16300000 24300000 Deletion Hughes'' syndrome
Sources

Expression for Antiphospholipid Syndrome

About this section
Search GEO for disease gene expression data for Antiphospholipid Syndrome.
Sources

Pathways for Antiphospholipid Syndrome

About this section

Pathways related to Antiphospholipid Syndrome according to GeneCards Suite gene sharing:

(show all 12)
# Super pathways Score Top Affiliating Genes
1
Response to elevated platelet cytosolic Ca2+ 65
Show member pathways
 13.08 VWF THBD SERPINC1 SELP SELE PROCR
2
Collagen chain trimerization 65
Show member pathways
 12.61 THBD SERPINC1 F5 F3 F2 F10
3
Cell surface interactions at the vascular wall 65
Show member pathways
 11.97 THBD SELP SELE PROCR F2
4
Cell adhesion molecules 36
11.93 VCAM1 SELP SELE CD40LG
5
Fluid shear stress and atherosclerosis 36
11.88 VCAM1 THBD SELE PLAT
6
Formation of Fibrin Clot (Clotting Cascade) 65
Show member pathways
 11.81 VWF THBD SERPINC1 PROCR PLAT F5
7
AGE-RAGE signaling pathway in diabetic complications 36
11.67 VCAM1 THBD SELE F3
8
Complement and coagulation cascades 36 1
11.48 VWF THBD SERPINC1 PROCR PLAT F5
9
Photodynamic therapy-induced NF-kB survival signaling 1
Show member pathways
 11.45 VCAM1 SELE CD40LG
10
Malaria 36
11.26 VCAM1 SELP SELE CD40LG
11
Warfarin Pathway, Pharmacodynamics 60
10.69 F2 F10
12
Dissolution of Fibrin Clot 65
10.61 PLAT ANXA2
Sources

GO Terms for Antiphospholipid Syndrome

About this section

Cellular components related to Antiphospholipid Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular exosome GO:0070062 10.06 VWF VCAM1 SERPINC1 PROCR PON1 PLAT
2 cell surface GO:0009986 9.91 VCAM1 THBD PROCR PLAT F3 CD40LG
3 external side of plasma membrane GO:0009897 9.85 VCAM1 THBD SELP F2 CD40LG
4 extracellular region GO:0005576 9.83 VWF SERPINC1 PROCR PON1 PLAT F5
5 endoplasmic reticulum lumen GO:0005788 9.8 SERPINC1 F5 F2 F10 ADAMTS13
6 collagen-containing extracellular matrix GO:0062023 9.76 VWF SERPINC1 PLAT F3 F2 APOH
7 blood microparticle GO:0072562 9.73 SERPINC1 PON1 F2 CFH
8 extracellular space GO:0005615 9.58 VWF VCAM1 THBD SERPINC1 SELP SELE
9 platelet alpha granule GO:0031091 9.48 VWF F5
10 intrinsic component of external side of plasma membrane GO:0031233 9.37 F3 F10

Biological processes related to Antiphospholipid Syndrome according to GeneCards Suite gene sharing:

(show all 21)
# Name GO ID Score Top Affiliating Genes
1 leukocyte migration GO:0050900 9.85 THBD SELP SELE F2
2 response to lipopolysaccharide GO:0032496 9.83 VCAM1 THBD SELP SELE
3 platelet activation GO:0030168 9.78 VWF F2 CD40LG ADAMTS13
4 heterophilic cell-cell adhesion via plasma membrane cell adhesion molecules GO:0007157 9.69 VCAM1 SELP SELE
5 platelet degranulation GO:0002576 9.65 VWF SELP F5 APOH ANXA5
6 hemostasis GO:0007599 9.65 VWF THBD SERPINC1 PROCR F5 F3
7 leukocyte tethering or rolling GO:0050901 9.63 VCAM1 SELP SELE
8 fibrinolysis GO:0042730 9.61 PLAT F2 ANXA2
9 positive regulation of blood coagulation GO:0030194 9.6 F2 APOH
10 negative regulation of blood coagulation GO:0030195 9.59 THBD APOH
11 plasminogen activation GO:0031639 9.58 PLAT APOH
12 negative regulation of platelet activation GO:0010544 9.58 THBD F2
13 blood coagulation, intrinsic pathway GO:0007597 9.58 VWF F2 APOH
14 positive regulation of leukocyte tethering or rolling GO:1903238 9.57 SELP SELE
15 positive regulation of binding GO:0051099 9.56 PON1 ANXA2
16 negative regulation of coagulation GO:0050819 9.54 PROCR ANXA5
17 regulation of blood coagulation GO:0030193 9.54 SERPINC1 F2 APOH
18 negative regulation of fibrinolysis GO:0051918 9.5 THBD F2 APOH
19 blood coagulation, extrinsic pathway GO:0007598 9.49 F3 F10
20 leukocyte cell-cell adhesion GO:0007159 9.46 VCAM1 SELP SELE CD40LG
21 blood coagulation GO:0007596 9.36 VWF THBD SERPINC1 PROCR PLAT F5

Molecular functions related to Antiphospholipid Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 serine-type endopeptidase activity GO:0004252 9.67 PLAT F3 F2 F10
2 integrin binding GO:0005178 9.62 VWF VCAM1 CD40LG ADAMTS13
3 protease binding GO:0002020 9.56 VWF SERPINC1 F3 ANXA2
4 calcium ion binding GO:0005509 9.56 THBD SELP PON1 F2 F10 ANXA5
5 heparin binding GO:0008201 9.55 SERPINC1 SELP F2 CFH APOH
6 oligosaccharide binding GO:0070492 9.43 SELP SELE
7 phospholipase inhibitor activity GO:0004859 9.4 ANXA5 ANXA2
8 phospholipid binding GO:0005543 9.02 PON1 F3 F10 APOH ANXA5
Sources

Sources for Antiphospholipid Syndrome

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....